Rhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($0.71) per share and revenue of $38.48 million for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Rhythm Pharmaceuticals Stock Down 2.1 %

RYTM traded down $1.21 during mid-day trading on Friday, reaching $56.53. 194,543 shares of the company traded hands, compared to its average volume of 457,099. The stock has a market capitalization of $3.47 billion, a P/E ratio of -13.03 and a beta of 2.14. The company's fifty day moving average price is $57.10 and its 200-day moving average price is $53.89. Rhythm Pharmaceuticals has a 52-week low of $35.17 and a 52-week high of $68.58.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Jefferies Financial Group assumed coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and issued a $80.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an "outperform" rating and a $76.00 price objective for the company. Finally, The Goldman Sachs Group upped their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $68.09.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, EVP Jennifer Kayden Lee sold 1,815 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $56.39, for a total transaction of $102,347.85. Following the completion of the transaction, the executive vice president now owns 3,598 shares of the company's stock, valued at $202,891.22. This represents a 33.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Christopher Paul German sold 635 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the transaction, the chief accounting officer now directly owns 2,070 shares of the company's stock, valued at $118,445.40. This trade represents a 23.48 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,787 shares of company stock valued at $1,901,443. Company insiders own 5.60% of the company's stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.